Crinetics Pharmaceuticals, Inc. (CRNX) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
CRNX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CRNX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 35.5% | -6714.8% | -6046.2% |
| 2024 | 100.0% | -32613.5% | -28720.7% |
| 2023 | 100.0% | -5547.2% | -5345.9% |
| 2022 | 100.0% | -3544.1% | -3460.4% |
| 2021 | 100.0% | -9990.9% | -9985.3% |
Download Data
Export CRNX earnings history in CSV or JSON format
Free sign-in required to download data
Crinetics Pharmaceuticals, Inc. (CRNX) Earnings Overview
As of May 8, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) reported trailing twelve-month net income of -$496M, reflecting -34.1% year-over-year growth. The company earned $-4.77 per diluted share over the past four quarters, with a net profit margin of -6046.2%.
Looking at the long-term picture, CRNX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2016.
Crinetics Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), CHRS ($168M net income, 398.4% margin), ACVA (-$62M net income, -8.7% margin), CRNX has room to improve margins relative to the peer group. Compare CRNX vs RCUS →
CRNX Earnings vs Peers
Earnings metrics vs comparable public companies
CRNX Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$465M | -55.9% | -$517M | $-4.95 | -6046.2% | -6714.8% |
| 2024 | -$298M | -39.1% | -$339M | $-3.69 | -28720.7% | -32613.5% |
| 2023 | -$215M | -30.9% | -$223M | $-3.69 | -5345.9% | -5547.2% |
| 2022 | -$164M | -52.3% | -$168M | $-3.15 | -3460.4% | -3544.1% |
| 2021 | -$108M | -45.8% | -$108M | $-2.80 | -9985.3% | -9990.9% |
| 2020 | -$74M | -49.0% | -$75M | $-2.42 | -103960.6% | -105567.6% |
| 2019 | -$50M | -82.7% | -$54M | $-2.05 | -4152.1% | -4512.3% |
| 2018 | -$27M | -196.1% | -$29M | $-2.23 | -1116.8% | -1182.5% |
| 2017 | -$9M | -52.1% | -$9M | $-0.66 | -447.8% | -446.3% |
| 2016 | -$6M | - | -$6M | $-0.43 | -1021.9% | -1026.1% |
See CRNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRNX — Frequently Asked Questions
Quick answers to the most common questions about buying CRNX stock.
Is CRNX growing earnings?
CRNX EPS fell to $-4.77, with earnings declining -34.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-496M.
What are CRNX's profit margins?
Crinetics Pharmaceuticals, Inc. net margin is -6046.2%, with operating margin at -6714.8%. Below-average margins reflect competitive or cost pressures.
How consistent are CRNX's earnings?
CRNX earnings data spans 2016-2025. The declining earnings trend is -34.1% YoY. Historical data enables comparison across business cycles.